International Journal of Clinical Research

Objective To explore and analyze the efficacy of cefoperazone and sulbactam combined with ambroxol hydrochloride in the treatment of chronic obstructive pulmonary disease. Methods A total of 102 patients with COPD in the hospital from January 2023 to January 2024 were selected. Based on the patients date of birth, the 102 patients were randomly divided into the control group and the observation group using random grouping. The control group was treated with cefoperazone-sulbactam, and the observation group was treated with cefoperazone-sulbactam combined with ambroxol hydrochloride. The treatment effects, lung function indicators, blood gas indicators, and quality of life of the two groups were compared. Results The treatment effect and quality of life of the observation group were higher than those of the control group, P<0.05. There was no significant difference in lung function indicators and blood gas indicators between the two groups before treatment, P>0.05. After treatment, the observation group was better than the control group, P<0.05. Conclusion Cefoperazone-sulbactam combined with ambroxol hydrochloride can significantly improve patients pulmonary function indicators and blood gas indicators, ensuring the sustainable improvement of patients treatment effects and quality of life.

Chronic obstructive pulmonary disease; Cefoperazone and sulbactam; Ambroxol hydrochloride; Therapeutic effect; Lung function indicators; Blood gas indicators; Quality of life